A Phase 2 interventional study of mRNA-1345 and Placebo in Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 50 sites in 2 countries. Open to participants aged 2 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases — none open to participants now, none under way, none of them phase 3. mRNA-1345 respiratory syncytial virus vaccine · Virus Diseases.
Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, this one is the 9th largest by enrollment, is one of 4 that started in 2023, is one of 2 in phase 2, and was the 8th registered.
656 studies on the registry are indexed under Virus Diseases; 84 are open to participants now.
Browse Virus Diseases studies →None of the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases is open now. The open studies under Virus Diseases, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 64 Virus Diseases studies recruiting now, 30 (47%) set no upper age limit and 22 (34%) stop at 75 or younger; 28 take children under 18; 27 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 5
First in 2020; this study’s year is marked. 4 started in 2023.
This study's enrollment of 349 is above the median of 100 across 464 interventional studies indexed under Virus Diseases.
Median enrollment 579 across the 10 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
47 studies in Virus Diseases by Moderna, Inc.: 2 open now, 6 under way, 1 of them phase 3. Of 40 finished, 17 (43%) have results posted.
Among the 47 studies in Virus Diseases by Moderna, Inc., this one is the 25th largest by enrollment of the 37 interventional ones that give a count, is one of 14 that started in 2023, is one of 10 in phase 2, and was the 35th registered.
Moderna, Inc.’s Virus Diseases studies by the year they started, since 2019.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, from their registry updates:
Among Moderna, Inc.’s 47 in Virus Diseases:
This tab as a report to print or save as PDF → With an account.
Part A: The purpose is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to \<5 years (Cohort 1) and in children at high risk of respiratory syncytial virus (RSV) disease 5 to \<18 years of age (Cohort 2) to inform the dose level selection for the next phase of development (Phase 3).
Part B: The purpose is to provide surveillance for RSV disease for the next RSV season (6 months after re-enrollment) and safety follow-up for Cohort 1 participants that were enrolled and dosed in Part A.
Key Inclusion Criteria:
Part A Cohort 1:
Cohort 2:
Part B: Cohort 1 Re-enrollment
Participants are eligible to be included in the study only if all of the following criteria apply:
Key Exclusion Criteria (All Cohorts):
Part B: Cohort 1 Re-enrollment
1. Participant is currently enrolled in another interventional clinical study.
Note: Other protocol-defined inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Participants 2 to \<5 years of age will receive either a single intramuscular (IM) injection of mRNA-1345 or placebo on Day 1. Part B: Participants will have the option to be re-enrolled into a 6-month safety-follow up period.
Biological: mRNA-1345 · Biological: Placebo
Participants 5 to \<18 years of age will receive a single IM injection of mRNA-1345 on Day 1.
Biological: mRNA-1345
Sterile liquid for injection
0.9% sodium chloride (normal saline) injection
Part A (Cohorts 1 and 2): Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to 7 days post-injection
Part A (Cohorts 1 and 2): Number of Participants With Unsolicited Adverse Events (AEs)
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to 28 days post-injection
Part A (Cohorts 1 and 2): Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interest (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Study Discontinuation
A MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Day 1 through end of Part A (Month 6)
Part B (Cohort 1): Number of Participants With RSV-RTD, Respiratory Syncytial Virus- Lower Respiratory Tract Disease (RSV-LRTD), Severe RSV-LRTD, Very Severe RSV-LRTD and RSV Hospitalization Classified by Clinical Assessment Team (CAT)
RSV-RTD: Runny nose or blocked nose or cough and confirmed RSV infection. RSV-LRTD: Cough or difficulty breathing (Based on Investigator's observation; difficulty breathing included signs of wheezing, stridor, tachypnoea, chest in-drawing or subcostal or intercostal retractions) and peripheral oxygen saturation (SpO2) \<95%, or respiratory rate (RR) increased and confirmed RSV infection. RSV Severe-LRTD: Meeting the definition of RSV-LRTD and SpO2 \<93%, or lower chest wall in-drawing. RSV Very Severe LRTD: Meeting the definition of RSV-LRTD and SpO2 \<90%, or failure to respond/unconscious. RSV Hospitalization: Confirmed RSV and hospitalized for acute medical condition.
Time frame: Day 1 through end of Part B (Month 6)
Part A (Cohort 1): Geometric Mean Titer (GMT) of Serum RSV Neutralizing Antibody
Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 international units (IU)/milliliter (mL) for RSV-A and 10 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 112476 IU/mL for RSV-B. 95% confidence interval (CI) for geometric mean (GM) value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.
Time frame: Day 1, Day 29, and Month 6
Part A (Cohort 1): Geometric Mean Concentration (GMC) of Serum RSV Prefusion F (Pre-F) Binding Antibody
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 arbitrary units (AU)/mL and ULOQ was 580553 AU/mL for RSV Pre-F immunoglobulin G (IgG) antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.
Time frame: Day 1, Day 29, and Month 6
Part A (Cohort 1): Geometric Mean Fold Rise (GMFR) of Post-baseline/Baseline Neutralizing Antibody Titers
Antibody values reported as below lower LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL for RSV-A and 10 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 112476 IU/mL for RSV-B. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
Time frame: Day 29 and Month 6
Part A (Cohort 1): GMFR of Post-baseline/Baseline Binding Antibody Concentrations
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 AU/mL and ULOQ was 580553 AU/mL for RSV Pre-F IgG antibody. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
Time frame: Day 29 and Month 6
Part A (Cohort 1): Percentage of Participants With Seroresponse in RSV Neutralizing Antibody
Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.
Time frame: Baseline to Day 29 and Month 6
Part A (Cohort 1): Percentage of Participants With Seroresponse in RSV Pre-F Binding Antibody
Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.
Time frame: Baseline to Day 29 and Month 6
Part A (Cohort 2): GMT of Serum RSV Neutralizing Antibody
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL for RSV-A and 15 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 162163 IU/mL for RSV-B. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.
Time frame: Day 1 and Day 29
Part A (Cohort 2): GMC of Serum RSV Pre-F Binding Antibody
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 AU/mL and ULOQ was 580553 AU/mL for RSV Pre-F IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.
Time frame: Day 1 and Day 29
Part A (Cohort 2): GMFR of Post-baseline/Baseline Neutralizing Antibody Titers
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL for RSV-A and 15 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 162163 IU/mL for RSV-B. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
Time frame: Day 29
Part A (Cohort 2): GMFR of Post-baseline/Baseline Binding Antibody Concentrations
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 AU/mL and ULOQ was 580553 AU/mL for RSV Pre-F IgG antibody. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
Time frame: Day 29
Part A (Cohort 2): Percentage of Participants With Seroresponse in RSV Neutralizing Antibody
Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.
Time frame: Baseline to Day 29
Part A (Cohort 2): Percentage of Participants With Seroresponse in RSV Pre-F Binding Antibody
Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.
Time frame: Baseline to Day 29
Part B (Cohort 1): Number of Participants With AESIs and SAEs
An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Day 1 through Part B EOS (Month 6)
| Milestone | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 2 | Part A Cohort 2: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 | Part B Cohort 1: Received Placebo in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 1 in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 2 in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 41 | 40 | 42 | 41 | 62 | 61 | 62 | 0 | 0 | 0 | 0 |
| Received study drug injection | 41 | 39 | 41 | 41 | 61 | 61 | 62 | 0 | 0 | 0 | 0 |
| Completed | 35 | 36 | 37 | 40 | 60 | 59 | 59 | 0 | 0 | 0 | 0 |
| Not completed | 6 | 4 | 5 | 1 | 2 | 2 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 3 | 4 | 1 | 0 | 2 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other than specified | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 2 | Part A Cohort 2: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 | Part B Cohort 1: Received Placebo in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 1 in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 2 in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 24 | 25 | 24 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19 | 24 | 25 | 23 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Solicited ARs were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 2 | Part A Cohort 2: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 |
|---|---|---|---|---|---|---|---|
| Part A (Cohorts 1 and 2): Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | 18 | 21 | 28 | 30 | 45 | 44 | 51 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 2 | Part A Cohort 2: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 |
|---|---|---|---|---|---|---|---|
| Part A (Cohorts 1 and 2): Number of Participants With Unsolicited Adverse Events (AEs) | 9 | 9 | 3 | 10 | 11 | 5 | 6 |
A MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 2 | Part A Cohort 2: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 |
|---|---|---|---|---|---|---|---|
| MAAEs | 3 | 4 | 5 | 9 | 10 | 8 | 9 |
| AESIs | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| AEs Leading to Study Discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RSV-RTD: Runny nose or blocked nose or cough and confirmed RSV infection. RSV-LRTD: Cough or difficulty breathing (Based on Investigator's observation; difficulty breathing included signs of wheezing, stridor, tachypnoea, chest in-drawing or subcostal or intercostal retractions) and peripheral oxygen saturation (SpO2) \<95%, or respiratory rate (RR) increased and confirmed RSV infection. RSV Severe-LRTD: Meeting the definition of RSV-LRTD and SpO2 \<93%, or lower chest wall in-drawing. RSV Very Severe LRTD: Meeting the definition of RSV-LRTD and SpO2 \<90%, or failure to respond/unconscious. RSV Hospitalization: Confirmed RSV and hospitalized for acute medical condition.
| Participants | Part B Cohort 1: Received Placebo in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 1 in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 2 in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A |
|---|---|---|---|---|
| RSV-RTD | 0 | 2 | 1 | 2 |
| RSV-LRTD | 0 | 1 | 0 | 0 |
| RSV Severe LRTD | 0 | 0 | 0 | 0 |
| RSV Very-Severe LRTD | 0 | 0 | 0 | 0 |
| RSV Hospitalization | 0 | 0 | 0 | 0 |
Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ. LLOQ was 13 international units (IU)/milliliter (mL) for RSV-A and 10 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 112476 IU/mL for RSV-B. 95% confidence interval (CI) for geometric mean (GM) value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.
| IU/mL | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 |
|---|---|---|---|---|
| RSV-A: Day 1 | 742.79 (406.66 to 1356.75) | 636.62 (335.51 to 1207.99) | 925.12 (553.23 to 1546.99) | 1100.06 (642.50 to 1883.48) |
| RSV-A: Day 29 | 622.62 (365.59 to 1060.36) | 7548.68 (4715.49 to 12084.11) | 5454.33 (3321.91 to 8955.59) | 13963.62 (8733.17 to 22326.68) |
| RSV-A: Month 6 | 767.32 (521.91 to 1128.13) | 1978.73 (1207.90 to 3241.47) | 1975.68 (1339.27 to 2914.51) | 4129.82 (2471.64 to 6900.43) |
| RSV-B: Day 1 | 343.19 (193.35 to 609.18) | 333.68 (187.03 to 595.33) | 478.93 (293.74 to 780.85) | 442.16 (266.78 to 732.83) |
| RSV-B: Day 29 | 310.51 (190.05 to 507.33) | 2439.14 (1542.12 to 3857.94) | 2043.38 (1282.91 to 3254.64) | 3913.01 (2665.38 to 5744.65) |
| RSV-B: Month 6 | 351.86 (259.00 to 478.01) | 708.25 (448.51 to 1118.41) | 746.17 (533.81 to 1043.00) | 975.64 (654.64 to 1454.04) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 arbitrary units (AU)/mL and ULOQ was 580553 AU/mL for RSV Pre-F immunoglobulin G (IgG) antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.
| AU/mL | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 |
|---|---|---|---|---|
| Day 1 | 5666.73 (2740.28 to 11718.45) | 4824.82 (2238.62 to 10398.78) | 7759.79 (4418.08 to 13629.08) | 9200.11 (5456.47 to 15512.24) |
| Day 29 | 5478.04 (2980.57 to 10068.20) | 60354.43 (43293.29 to 84139.08) | 52861.15 (36058.06 to 77494.50) | 93443.87 (69910.72 to 124898.70) |
| Month 6 | 6021.94 (4130.25 to 8780.02) | 13070.48 (8101.85 to 21086.21) | 14422.57 (10902.68 to 19078.86) | 20054.12 (13907.99 to 28916.31) |
Antibody values reported as below lower LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL for RSV-A and 10 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 112476 IU/mL for RSV-B. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
| ratio | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 |
|---|---|---|---|---|
| RSV-A: Day 29 | 0.84 (0.68 to 1.04) | 11.86 (7.23 to 19.43) | 5.90 (3.55 to 9.79) | 12.69 (7.74 to 20.82) |
| RSV-A: Month 6 | 0.90 (0.57 to 1.40) | 3.66 (2.41 to 5.56) | 1.70 (0.95 to 3.05) | 3.78 (2.33 to 6.13) |
| RSV-B: Day 29 | 0.81 (0.66 to 0.99) | 7.31 (4.82 to 11.08) | 4.27 (2.74 to 6.64) | 8.85 (5.59 to 14.02) |
| RSV-B: Month 6 | 0.99 (0.65 to 1.53) | 2.46 (1.72 to 3.52) | 1.23 (0.74 to 2.04) | 2.12 (1.30 to 3.45) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 AU/mL and ULOQ was 580553 AU/mL for RSV Pre-F IgG antibody. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
| ratio | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 |
|---|---|---|---|---|
| Day 29 | 0.94 (0.76 to 1.17) | 13.43 (6.78 to 26.58) | 6.63 (4.18 to 10.52) | 10.16 (6.53 to 15.79) |
| Month 6 | 0.81 (0.48 to 1.37) | 2.86 (1.68 to 4.87) | 1.28 (0.81 to 2.05) | 2.16 (1.41 to 3.33) |
Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.
| percentage of participants | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 |
|---|---|---|---|---|
| RSV-A: Day 29 | 2.6 (0.1 to 13.5) | 78.9 (62.7 to 90.4) | 46.3 (30.7 to 62.6) | 79.5 (63.5 to 90.7) |
| RSV-A: Month 6 | 9.1 (1.9 to 24.3) | 50.0 (32.4 to 67.6) | 28.6 (14.6 to 46.3) | 52.6 (35.8 to 69.0) |
| RSV-B: Day 29 | 0 (0.0 to 9.5) | 63.2 (46.0 to 78.2) | 48.8 (32.9 to 64.9) | 71.8 (55.1 to 85.0) |
| RSV-B: Month 6 | 9.1 (1.9 to 24.3) | 26.5 (12.9 to 44.4) | 22.9 (10.4 to 40.1) | 39.5 (24.0 to 56.6) |
Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.
| percentage of participants | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 |
|---|---|---|---|---|
| Day 29 | 2.6 (0.1 to 13.8) | 75.0 (57.8 to 87.9) | 53.8 (37.2 to 69.9) | 74.4 (57.9 to 87.0) |
| Month 6 | 6.3 (0.8 to 20.8) | 21.9 (9.3 to 40.0) | 17.1 (6.6 to 33.6) | 36.8 (21.8 to 54.0) |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL for RSV-A and 15 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 162163 IU/mL for RSV-B. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.
| IU/mL | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 |
|---|---|---|---|
| RSV-A: Day 1 | 1260.25 ± 943.55 | 1027.77 ± 749.05 | 1230.06 ± 946.64 |
| RSV-A: Day 29 | 10168.70 ± 7560.52 | 9011.13 ± 6239.70 | 19541.50 ± 15311.61 |
| RSV-B: Day 1 | 669.76 ± 506.07 | 617.58 ± 449.58 | 581.70 ± 463.11 |
| RSV-B: Day 29 | 3105.78 ± 2498.97 | 3523.27 ± 2598.78 | 4782.51 ± 4006.02 |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 AU/mL and ULOQ was 580553 AU/mL for RSV Pre-F IgG antibody. 95% CI for GM value was calculated based on the t-distribution of the log-transformed values, then back transformed to the original scale for presentation.
| AU/mL | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 |
|---|---|---|---|
| Day 1 | 11060.58 ± 8799.38 | 9556.54 ± 7002.35 | 11882.31 ± 10029.95 |
| Day 29 | 67394.60 ± 54544.98 | 69494.70 ± 55349.62 | 109004.49 ± 94312.25 |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ. LLOQ was 13 IU/mL for RSV-A and 15 IU/mL for RSV-B. ULOQ was 259061 IU/mL for RSV-A and 162163 IU/mL for RSV-B. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
| ratio | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 |
|---|---|---|---|
| RSV-A | 8.07 ± 6.17 | 8.77 ± 6.26 | 15.89 ± 11.92 |
| RSV-B | 4.64 ± 3.61 | 5.71 ± 4.21 | 8.22 ± 6.53 |
Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than ULOQ were replaced by the ULOQ. LLOQ was 35 AU/mL and ULOQ was 580553 AU/mL for RSV Pre-F IgG antibody. 95% CI for GMFR (post-injection/baseline titers) was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
| ratio | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 |
|---|---|---|---|
| Part A (Cohort 2): GMFR of Post-baseline/Baseline Binding Antibody Concentrations | 6.09 ± 4.77 | 7.27 ± 5.43 | 9.17 ± 7.65 |
Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.
| percentage of participants | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 |
|---|---|---|---|
| RSV-A | 76.3 ± 63.4 | 75.9 ± 62.8 | 86.7 ± 75.4 |
| RSV-B | 54.2 ± 40.8 | 60.3 ± 46.6 | 71.7 ± 58.6 |
Seroresponse was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold increase if baseline was equal to or above the LLOQ.
| percentage of participants | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 |
|---|---|---|---|
| Part A (Cohort 2): Percentage of Participants With Seroresponse in RSV Pre-F Binding Antibody | 69.5 ± 56.1 | 74.1 ± 61.0 | 88.3 ± 77.4 |
An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor are required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part B Cohort 1: Received Placebo in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 1 in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 2 in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A |
|---|---|---|---|---|
| AESIs | 0 | 1 | 0 | 0 |
| SAEs | 0 | 0 | 1 | 0 |
Collected over All-cause mortality, SAEs, AESIs, MAAEs, and AEs leading to study discontinuation: up to Month 6 (Parts A & B). Other (non-serious) AEs: up to 28 days after study injection, unless they met criteria for AESIs, MAAEs, or AEs led to study discontinuation.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A Cohort 1: Placebo | 0/41 (0%) | 0/41 (0%) | 1/41 (2.4%) |
| Part A Cohort 1: mRNA-1345 Dose Level 1 | 0/39 (0%) | 0/39 (0%) | 3/39 (7.7%) |
| Part A Cohort 1: mRNA-1345 Dose Level 2 | 0/41 (0%) | 0/41 (0%) | 1/41 (2.4%) |
| Part A Cohort 1: mRNA-1345 Dose Level 3 | 0/41 (0%) | 0/41 (0%) | 7/41 (17.1%) |
| Part A Cohort 2: mRNA-1345 Dose Level 2 | 0/61 (0%) | 0/61 (0%) | 5/61 (8.2%) |
| Part A Cohort 2: mRNA-1345 Dose Level 3 | 0/61 (0%) | 0/61 (0%) | 0/61 (0%) |
| Part A Cohort 2: mRNA-1345 Dose Level 4 | 0/62 (0%) | 3/62 (4.8%) | 0/62 (0%) |
| Part B Cohort 1: Received Placebo in Part A | 0/19 (0%) | 0/19 (0%) | 0/19 (0%) |
| Part B Cohort 1: Received mRNA-1345 Dose Level 1 in Part A | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
| Part B Cohort 1: Received mRNA-1345 Dose Level 2 in Part A | 0/25 (0%) | 1/25 (4%) | 0/25 (0%) |
| Part B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A | 0/24 (0%) | 0/24 (0%) | 0/24 (0%) |
| Event | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 2 | Part A Cohort 2: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 | Part B Cohort 1: Received Placebo in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 1 in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 2 in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A |
|---|---|---|---|---|---|---|---|---|---|---|---|
| InfluenzaInfections and infestations | 0/41 | 0/39 | 0/41 | 0/41 | 0/61 | 0/61 | 0/62 | 0/19 | 0/24 | 1/25 | 0/24 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/41 | 0/39 | 0/41 | 0/41 | 0/61 | 0/61 | 2/62 | 0/19 | 0/24 | 0/25 | 0/24 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/41 | 0/39 | 0/41 | 0/41 | 0/61 | 0/61 | 1/62 | 0/19 | 0/24 | 0/25 | 0/24 |
| Event | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 2 | Part A Cohort 2: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 | Part B Cohort 1: Received Placebo in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 1 in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 2 in Part A | Part B Cohort 1: Received mRNA-1345 Dose Level 3 in Part A |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 1/41 | 1/39 | 0/41 | 4/41 | 3/61 | 0/61 | 0/62 | 0/19 | 0/24 | 0/25 | 0/24 |
| Pharyngitis streptococcalInfections and infestations | 0/41 | 0/39 | 1/41 | 3/41 | 1/61 | 0/61 | 0/62 | 0/19 | 0/24 | 0/25 | 0/24 |
| Gastroenteritis viralInfections and infestations | 0/41 | 2/39 | 0/41 | 0/41 | 1/61 | 0/61 | 0/62 | 0/19 | 0/24 | 0/25 | 0/24 |
The Randomization Set included all participants who were randomized in the study, regardless of the participant's treatment status in the study. For Part B, all Cohort 1 participants who were enrolled and dosed in Part A, were offered to re-enroll into the safety follow-up study.
| Age, Customized(Participants) | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 2 | Part A Cohort 2: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 | Total |
|---|---|---|---|---|---|---|---|---|
| In utero | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Children (2-11 years) | 41 | 40 | 42 | 41 | 30 | 30 | 31 | 255 |
| Adolescents (12-17 years) | 0 | 0 | 0 | 0 | 32 | 31 | 31 | 94 |
| Adults (18-64 years) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 2 | Part A Cohort 2: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 20 | 22 | 17 | 26 | 33 | 23 | 35 | 176 |
| Male | 21 | 18 | 25 | 15 | 29 | 38 | 27 | 173 |
| Ethnicity (NIH/OMB)(Participants) | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 2 | Part A Cohort 2: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 14 | 11 | 14 | 19 | 14 | 17 | 15 | 104 |
| Not Hispanic or Latino | 27 | 29 | 28 | 22 | 48 | 44 | 47 | 245 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A Cohort 1: Placebo | Part A Cohort 1: mRNA-1345 Dose Level 1 | Part A Cohort 1: mRNA-1345 Dose Level 2 | Part A Cohort 1: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 2 | Part A Cohort 2: mRNA-1345 Dose Level 3 | Part A Cohort 2: mRNA-1345 Dose Level 4 | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 14 | 11 | 6 | 8 | 20 | 31 | 28 | 118 |
| White | 25 | 26 | 32 | 30 | 38 | 27 | 31 | 209 |
| More than one race | 1 | 2 | 3 | 1 | 3 | 3 | 2 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2023 to primary completion in Jun 2025, 20 months.
Results were first posted in Aug 2026, 1 year 1 month after primary completion.
Of 34 industry-sponsored phase 2 interventional studies under Virus Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 20 months is above that.
Counting every sponsor, half of 58 studies reached it within 16 months; a quarter within 10 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: mRNA-1345 respiratory syncytial virus vaccine